{"nctId":"NCT05629962","briefTitle":"SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19","startDateStruct":{"date":"2022-11-25","type":"ACTUAL"},"conditions":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)","COVID-19"],"count":2285,"armGroups":[{"label":"Bemnifosbuvir (BEM)","type":"EXPERIMENTAL","interventionNames":["Drug: Bemnifosbuvir (BEM)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Bemnifosbuvir (BEM)","otherNames":["AT-527"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Positive SARS-CoV-2 test conducted ≤ 5 days prior to randomization\n* Mild or moderate COVID-19 with symptom onset ≤ 5 days before randomization and at least one COVID-19 related symptom present at time of screening\n* Subject must be high risk, defined below:\n\n  1. Age ≥70 years OR\n  2. Age ≥55 years with one of the following: i) obesity (body mass index \\[BMI\\] ≥30 kg/m2) ii) diabetes mellitus iii) cardiovascular disease or hypertension iv) chronic lung disease requiring routine therapy OR\n  3. Age 50 to 54 years with two of the following: i) obesity (BMI ≥30 kg/m2) ii) diabetes mellitus iii) cardiovascular disease or hypertension iv) chronic lung disease requiring routine therapy OR\n  4. Age ≥18 years with one of the following: i) Down syndrome, sickle cell disease, dementia, Parkinson's disease, or care home residents ii) One of the following immunocompromising conditions or immunosuppressive treatments: receiving chemotherapy for cancer, hematologic malignancy, being within 2 years of a hematopoietic stem cell transplant, receipt of a solid organ transplant and on immunosuppressive therapy, human immunodeficiency virus (HIV) infection untreated or with CD4+ T lymphocyte count \\<350 cells per cubic millimeter, moderate/severe primary immunodeficiency, taking immunosuppressive medications\n* Use of adequate contraception for females of childbearing potential\n\nExclusion Criteria:\n\n* Severe or critical COVID-19 illness\n* Admitted to a hospital within 90 days prior to randomization due to COVID-19\n* Use of other investigational drugs within 30 days prior to planned dosing, or plans to enroll in another clinical trial of an investigational agent while participating in the present study\n* Initiation or planned initiation of remdesivir for treatment of the current SARS-CoV-2 infection\n* Requirement of prohibited medications, including hydroxychloroquine or amiodarone within 3 months prior to screening. Note: Subjects who had already initiated any COVID-19 drug with antiviral effects intended to treat symptomatic SARS-CoV-2 infection (≥ 24 hours prior to randomization) will be excluded. During screening (or within 24 hours prior to or after randomization), locally available COVID-19 drugs with antiviral effects (including but not limited to nirmatrelvir/ritonavir, molnupiravir, favipiravir, monoclonal antibodies) will be permitted.\n* Other known active viral or bacterial infection at the time of screening, such as influenza and respiratory syncytial virus (RSV). Note: This exclusion does not apply to subjects with stable chronic viral infections, such as chronic hepatitis C virus (HCV) or HIV providing other eligibility criteria are met.\n* Receiving dialysis or have known severe renal impairment\n* History of severe hepatic impairment (Child-Pugh Class C)\n* Known allergy or hypersensitivity to components of study drug","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Hospitalized for Any Cause or Died Due to Any Cause","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Hospitalized Due to COVID-19 or Died Due to Any Cause","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Died Due to Any Cause","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With COVID-19-related Complications","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With COVID-19-medically Attended Visits (Hospitalization, Emergency Room (ER) Visit, Urgent Care Visit, Physician's Office Visit, or Telemedicine Visit) or Who Died Due to Any Cause","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With COVID-19 Symptom Relapse","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"272","spread":null},{"groupId":"OG001","value":"265","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Viral Load Rebound","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"102","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":1093},"commonTop":["Diarrhoea","Nausea","Hypercholesterolaemia","Hyponatraemia","Dysguesia"]}}}